Madrigal Pharmaceuticals Q2 2024 GAAP EPS $(7.10) Beats $(7.58) Estimate, Sales $14.638M Beat $3.903M Estimate
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals reported its Q2 2024 financial results, with a GAAP EPS of $(7.10), beating the estimate of $(7.58). The company also reported sales of $14.638 million, significantly surpassing the estimate of $3.903 million.
August 07, 2024 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals reported better-than-expected Q2 2024 financial results, with a GAAP EPS of $(7.10) beating the estimate of $(7.58) and sales of $14.638 million significantly surpassing the estimate of $3.903 million.
The better-than-expected earnings and sales figures are likely to positively impact Madrigal Pharmaceuticals' stock price in the short term. Beating both EPS and sales estimates typically boosts investor confidence and can lead to a stock price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100